Freenome

## Overview Freenome is a private biotechnology company focused on the development of blood tests for early cancer detection. The company utilizes a multiomics platform that integrates computational biology, machine learning, and various data types to identify cancer signals. Freenome's approach aims to detect cancer in its early, more treatable stages, with an emphasis on making screening accessible. The company's initial product focus is on colorectal cancer (CRC) with its SimpleScreen™ CRC test, which uses a blood sample to detect signs of cancer and precancerous growths. Freenome is also engaged in clinical studies for lung cancer and other cancer types. Founded in 2014, Freenome has approximately 400 employees. ## Key Features * **Multiomics Platform:** Combines tumor and non-tumor signals with machine learning and multiple data types for early cancer detection. * **Blood-Based Screening:** Develops tests that rely on a standard blood draw, aiming to simplify the screening process. * **Colorectal Cancer Test (SimpleScreen™ CRC):** A blood test designed for the early detection of colorectal cancer and advanced adenomas. * **Clinical Study Programs:** Conducts large-scale clinical trials, including the PREEMPT CRC® Study (colorectal cancer), PROACT LUNG Study (lung cancer), and the Vallania Study (multiple cancer types). * **CLIA Certified Laboratory:** Operates a Clinical Laboratory Improvement Amendments of 1988 (CLIA) certified laboratory for high complexity clinical testing. ## Who It's For Freenome's services are intended for healthcare providers and health systems seeking non-invasive, blood-based screening options for early cancer detection. This includes practitioners looking for alternatives or complements to existing screening methods, particularly for colorectal cancer, and those interested in emerging technologies for lung cancer and other cancer types. The company's focus on accessibility also suggests relevance for initiatives aimed at increasing screening rates in diverse populations. ## Notable Strengths Freenome's strengths include its multiomics approach, which seeks to identify subtle cancer cues by integrating various biological data. The company's commitment to rigorous clinical validation is demonstrated by its large-scale studies, such as the PREEMPT CRC® Study, which enrolled over 40,000 participants. The SimpleScreen™ CRC test offers a blood-based alternative for colorectal cancer screening, potentially reducing barriers associated with traditional methods. Freenome is actively expanding its research into other high-need cancer types, indicating a long-term development pipeline.